Zofroxia (CB2007) / Canopus BioPharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   2 News 
  • ||||||||||  Zofroxia (CB2007) / Canopus BioPharma
    Journal:  Identification of Type 4B Secretion System Substrates That Are Conserved among Coxiella burnetii Genomes and Promote Intracellular Growth. (Pubmed Central) -  Jun 19, 2023   
    CRISPR interference (CRISPRi) indicated that of the validated C. burnetii T4BSS substrates, CBU0122, CBU1752, CBU1825, and CBU2007 promote C. burnetii replication in THP-1 cells and CCV biogenesis in Vero cells...Several T4BSS substrates that were validated in C. burnetii also promoted pathogen intracellular replication and one trafficked to late endosomes and the mitochondria in a manner suggestive of effector activity. This study identified several bona fide C. burnetii T4BSS substrates and further refined the methodological criteria for their designation.